Water-soluble fractions have been purified from the crude aqueous extracts of Artemisia species, especially from Artemisia folum (AVF3) and Artemisia iwayomogi Kitam. (AIP1). The herbs are traditionally used as the medicinal plant to prevent
or treat a number of liver diseases in Asia [1]. The AIP1 fraction has been shown
to have diverse immuno-modulating activities including, anti-apoptosis and anti-cancer
effects in our previous works [2, 3]. In this study, we have investigated the anti-inflammatory
activity of the fractions using the LPS-induced inflammation model with primary rat
astrocyte cultures. The treatment of the astrocyte culture either with AVF3 or AIP1
resulted in the suppression of the NO production by the LPS treatment, which was comparable
to that of the dexamethasone treatment. Quantitative real-time PCR analysis revealed
that the expression of iNOS gene was significantly suppressed by the samples, indicating
that the inhibition of NO production could result from an inhibitory effect on iNOS
gene transcription. The treatment also suppressed the up-regulation of the pro-inflammatory
IL-6 and MIP-1β genes as the dexamethasone treatment. These results clearly demonstrate
that the water-soluble fractions from Artemisia species might modulate the inflammatory response in brain astrocytes. Since NO production
in brain astrocytes is important in the pathogenesis of a number of brain inflammatory
diseases such as multiple sclerosis and Alzheimer's disease, the anti-inflammatory
effect of the fraction could have considerable value for the protection or the treatment
of the neurodegenerative diseases.
Acknowledgement: This study was supported by a grant from the Ministry of Commerce, Industry and Energy
(MOCIE) and the Korea Institute of Industrial Technology Evaluation & Planning (ITEP)
through the Biohealth Products Research Center of Inje University.
References: 1. Bensky, D. et al. (2004), Chinese Herbal Medicine; Materia Medica. Eastland Press Inc. Seattle, USA.
2. Koo, K.A. et al. (1994), Arch. Pharm. Res. 17: 371–374. 3. Hwang, J.S. et al. (2005), Biol. Pharm. Bull. 28: 921–924.
